Buyang Huanwu decoction ameliorates coronary heart disease with Qi deficiency and blood stasis syndrome by reducing CRP and CD40 in rats

Journal of Ethnopharmacology

Volumn 130, Issue 1, 2010, Pages 98-102

  Zhang, Hui ^a   Wang, Wei Rong ^a   Lin, Rong ^a   Zhang, Ji Ye ^a   Ji, Qiao Li ^a   Lin, Qin Qin ^a   Yang, Li Na ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Buyang Huanwu decoction (BYHWD); C reactive protein (CRP); Cluster of differentiation 40 (CD40); Coronary heart disease (CHD); Endothelium derived vasoactive factors

Indexed keywords

BIOLOGICAL MARKER; BUYANG HUANWU EXTRACT; C REACTIVE PROTEIN; CHINESE DRUG; CLUSTER OF DIFFERENTIATION 40; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PLANT EXTRACT; PROSTACYCLIN; THROMBOXANE A2; TONGXINLUO; UNCLASSIFIED DRUG; VASOACTIVE AGENT; BUYANG HUANWU; CD40 ANTIGEN; HERBACEOUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD LEVEL; BLOOD STASIS SYDROME; BLOOD STASIS SYNDROME; CHINESE MEDICINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HEART; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; QI DEFICIENCY; RAT; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; CORONARY DISEASE; HEMOSTASIS; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD40; C-REACTIVE PROTEIN; CORONARY DISEASE; DRUGS, CHINESE HERBAL; EPOPROSTENOL; FEMALE; HEMOSTASIS; MEDICINE, CHINESE TRADITIONAL; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; QI; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE A2;

RATTUS;

EID: 77953808121     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.04.017     Document Type: Article

References (33)

1. Blaton V. CD40: a new marker in coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation 2007, 67:113.
2. Cai D.M., Yin S.L., Wu W.K. The clinical efficacy of Buyang Huanwu Decoction with CHD with qi deficiency and blood stasis syndrome and NO level change in plasma. Modern Medical Journal 2004, 32:25-28.
3. Cai G., Liu B., Liu W., Tan X., Rong J., Chen X., Tong L., Shen J. Buyang Huanwu Decoction can improve recovery of neurological function, reduce infarction volume, stimulate neural proliferation and modulate VEGF and Flk1 expressions in transient focal cerebral ischaemic rat brains. Journal of Ethnopharmacology 2007, 113:292-299.
4. Chai, C.Z., Kou, J.P., Zhu, D.N., Yan, Y.Q., Yu, B.Y., 2010. Mice exposed to chronic intermittent hypoxia simulate clinical features of deficiency of both Qi and Yin syndrome in traditional chinese medicine. Evidence-based complementary and alternative medicine advance access (published online on January 3, 2010).
5. Chen Q.X., Zhou H.W. Buyang Huanwu Decoction can improve the life quality of CHD with Qi deficiency and blood stasis syndrome. Yun Nan Zhong Yi Zhong Yao Za Zhi 2007, 28:25-26.
6. China Pharmacopoeia Committee Pharmacopoeia of the People's Republic of China (in Chinese) 2000, China Chemical Industry Press, Beijing.
7. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., Lowe G.D., Pepys M.B., Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine 2004, 350:1387-1397.
8. de Leval X., Hanson J., David J.L., Masereel B., Pirotte B., Dogné J.M. New developments on thromboxane and prostacyclin modulators. Part II. Prostacyclin modulators. Current Medicinal Chemistry 2004, 11:1243-1252.
9. Erbaĝci A.B., Tarakçioĝlu M., Aksoy M., Kocabaş R., Nacak M., Aynacioĝlu A.S., Sivrikoz C. Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiologica 2002, 57:197-204.
10. 2 levels in normal and preeclamptic pregnancies. Tohoku Journal of Experimental Medicine 1991, 165:79-86.
11. Han S.J., Liu Z.L. The effects of BuYang HuanWu decoction on inflammatory cellular factors in blood serums after the injury of cerebral ischemia and reperfusion in gerbils. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 2004, 4:1-3.
12. Haywood G.A., Tsao P.S., vonderLeyen H.E., Mann M.J., Kelling P.J., Trindade P.T., Lewis N.P., Byrne C.D., Rickenbacher P.R., Bishopric N.H., Cooke J.P., McKenna W.J., Fowler M.B. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996, 93:1087-1094.
13. Huang F.H. The discussion on dosage problem in the materials of new Chinese medicine declaration. Research and Information on Traditional Chinese Medicine 2004, 6:26-28.
14. Li R., Wang W.Q., Zhang H.F., Yang X.C., Fan Q., Theodore A.C., Bernard L.L., Tao L., Barry J.G., Gao F., Xin L., Ma S. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. American Journal of Physiology Endocrinology and Metabolism 2007, 293:E1703-E1708.
15. Li S.P. Progress on treatment of coronary heart disease with integrated traditional Chinese medicine and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993, 13:755-757.
16. Li Y.K. Experimental Methodology of TCM Pharmacology 1991, Shanghai Science and Technology Publishing House, Shanghai.
17. Massion P.B., Feron O., Dessy C., Balligand J.L. Nitric oxide and cardiac function-Ten years after, and continuing. Circulation Research 2003, 93:388-398.
18. Miao Y., Zhao W.J., Jing L. Retrospective analysis on integrative medicinal treatment of chronic heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008, 28:406-409.
19. Patrick L., Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Alternative Medicine Review 2001, 6:248-271.
20. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
21. Rizvi M., Pathak D., Freedman J.E., Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends in Molecular Medicine 2008, 14:530-538.
22. Tanne D., Haim M., Goldbourt U., Boyko V., Reshef T., Adler Y., Benderly M., Mekori Y.A., Behar S. CD40 ligand and risk of ischemic stroke or coronary events in patients with chronic coronary heart disease. International Journal of Cardiology 2006, 107:322-326.
23. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., Dhillon B., Weisel R.D., Li R.K., Mickle D.A., Stewart D.J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
24. Wang J., Chu F.Y., Li J., Yao K.W., Zhong J.B., Zhou K.H., He Q.Y., Sun X.W. Study on Syndrome element characteristics and its correlation with coronary angiography in 324 patients with coronary heart disease. Journal of Chinese Integrative Medicine 2008, 14:274-280.
25. Wang Y., Li L., Tan H.W., Yu G.S., Ma Z.Y., Zhao Y.X., Zhang Y. Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease. Clinical Cardiology 2007, 30:86-91.
26. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-10.
27. Wu H.L., Ruan X.M., Yang X.B. Analysis on TCM syndrome distribution laws in 319 patients with coronary heart disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007, 27:498-500.
28. Yang, G., Fang, Z., Liu, Y., Zhang, H., Shi, X., Ji, Q., Lin, Q., Lin, R., 2009. Protective effects of chinese traditional medicine Buyang Huanwu decoction on myocardial injury. Evidence-based Complementary and Alternative Medicine (Feb. 8).
29. Yin J.X., Tian J.Z., Song C.S., Ship J., Ren Y., Hu Q., Wang Y.Y. The establishment and evaluation on qi deficiency and blood stasis animal model. Zhonghua Zhongyiyao Zazhi 2006, 21:424-426.
30. You S.J., Chen K.J., Yang Y.J., Gao R., Wu Y., Zhang J., Wang Y., Chen J. Clinical study on spontaneous improvement after blood flow reconstruction interfered by tongxinluo capsule in patients with early stage acute myocardial infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005, 25:604-607.
31. Zhang H., Liang M.J., Ma Z.X. Clinical study on effects of buyang huanwu decoction on coronary heart disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995, 15:213-215.
32. Zhang L., Wu Y.L., Jia Z.H., Zhang Y., Shen H.Y., Wang X.L. Protective effects of a compound herbal extract (Tong Xin Luo) on free fatty acid induced endothelial injury: Implications of antioxidant system. BMC Complementary and Alternative Medicine 2008, 8:39-49.
33. Zhang Y.L., Zhang J., Hu X.G. Establishment of rat model of ischemic stroke with qi deficiency and blood stasis syndrome and its evaluation system. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009, 29:343-346.